𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The safety and efficacy of a powered toothbrush on soft tissues in patients with implant-supported fixed prostheses

✍ Scribed by B. Vandekerckhove; M. Quirynen; P. R. Warren; J. Strate; D. van Steenberghe

Publisher
Springer
Year
2004
Tongue
English
Weight
202 KB
Volume
8
Category
Article
ISSN
1432-6981

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy of a combination of etoposi
The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma
✍ Zs. Pápai; Gy. Bodoky; J. Szántó; I. Poller; P. Rahóty; S. Eckhardt; I. Láng; M. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

## BACKGROUND. Successful chemotherapy for patients with soft tissue sarcoma (STS) has been limited by a lack of active drugs. The most effective single agents are doxorubicin, dacarbazine, and, more recently, ifosfamide. Previously the most widely used combination has been CYVADIC (cyclophosphami

A double-blind, placebo-controlled evalu
A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures
✍ T Rentmeester; A Janssen; J Hulsman; F Scholtes; B van der Kleij; J Overweg; J M 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 655 KB

Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on-trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1-2 mg/l. In spite of an antiepileptic therapy, u

Long-term evaluation of the efficacy and
Long-term evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures: a 1-year open follow-up
✍ T. Rentmeester; A. Janssen; J. Hulsman; F. Scholtes; B. van der Kleij; J. Overwe 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 534 KB

The effect and safety of loreclezole were evaluated during a long-term follow-up trial targeting higher plasma concentrations than those of the preceding controlled trial. The result is better than in the double-blind trial, in which loreclezole doses were administered to reach plasma concentrations

Efficacy and safety of the PPARγ partial
Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
✍ Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; B 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract ## Background Treatment of patients with perioxisome proliferator‐activated receptor‐γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator‐activated receptor‐γ agonists has not been esta